BioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 112,400 Shares

BioSyent Inc. (CVE:RX) insider FAX Capital Corp. sold 112,400 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total transaction of C$1,267,557.28.

FAX Capital Corp. also recently made the following trade(s):

• On Friday, November 22nd, FAX Capital Corp. sold 230,800 shares of BioSyent stock. The shares were sold at an average price of C$11.12, for a total value of C$2,566,496.00.

BioSyent Price Performance

Shares of BioSyent stock traded down C$0.09 during trading on Monday, hitting C$11.65. The stock had a trading volume of 5,376 shares, compared to its average volume of 6,537. The company has a debt-to-equity ratio of 3.19, a current ratio of 6.13 and a quick ratio of 6.91. The business has a fifty day moving average of C$11.29 and a two-hundred day moving average of C$10.64. BioSyent Inc. has a fifty-two week low of C$8.24 and a fifty-two week high of C$12.13. The firm has a market cap of C$135.02 million, a P/E ratio of 19.42 and a beta of 0.93.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.